As most RNA sensors have function on anti-tumor immunity based on their induction of IFN signaling [84], many drugs targeting RNA sensors are under clinical evaluation for cancer treatment (data from https://clinicaltrials.gov/) (Table 3). Here, IFNA1 is linked to neoplasm.